# reload+after+2024-01-21 07:48:02.607517
address1§Marina One East Tower
address2§7 Straits View No.12-00
city§Singapore
zip§018936
country§Singapore
phone§65 6236 3388
website§https://www.wavelifesciences.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.
fullTimeEmployees§250
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Paul B.  Bolno M.B.A., M.D.', 'age': 49, 'title': 'President, CEO & Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1102777, 'exercisedValue': 0, 'unexercisedValue': 989993}, {'maxAge': 1, 'name': 'Mr. Kyle B.  Moran CFA', 'age': 52, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 677867, 'exercisedValue': 0, 'unexercisedValue': 113000}, {'maxAge': 1, 'name': 'Dr. Chandra  Vargeese Ph.D.', 'age': 62, 'title': 'CTO & Head of Platform Discovery Sciences', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 710054, 'exercisedValue': 0, 'unexercisedValue': 930957}, {'maxAge': 1, 'name': 'Kate  Rausch', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Linda  Rockett J.D.', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher  Francis Ph.D.', 'age': 45, 'title': 'Senior VP of Corporate Development & Head of Emerging Areas', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 493131, 'exercisedValue': 4748295, 'unexercisedValue': 2277077}, {'maxAge': 1, 'name': 'Ms. Daryn  Lewis', 'title': 'Senior VP & Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sridhar  Vaddeboina Ph.D.', 'title': 'Senior Vice President of Chemistry, Manufacturing & Controls', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne-Marie  Li-Kwai-Cheung', 'title': 'Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hsiu-Chiung  Yang Ph.D.', 'title': 'Senior Vice President of Translational Medicine', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§2
compensationRisk§7
shareHolderRightsRisk§3
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-1.202
priceToSalesTrailing12Months§6.884495
currency§USD
dateShortInterest§1702598400
forwardEps§-0.95
exchange§NGM
quoteType§EQUITY
shortName§Wave Life Sciences Ltd.
longName§Wave Life Sciences Ltd.
firstTradeDateEpochUtc§1447252200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b166faa2-4f38-3226-ab53-f1e915ebcf51
gmtOffSetMilliseconds§-18000000
targetHighPrice§17.0
targetLowPrice§5.0
targetMeanPrice§9.21
targetMedianPrice§8.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§1.47
grossMargins§-0.48574
ebitdaMargins§-1.0229
trailingPegRatio§None
